Showing 1,001 - 1,020 results of 53,759 for search '(( 5 ((non decrease) OR (mean decrease)) ) OR ( 50 ((mg decrease) OR (a decrease)) ))', query time: 1.21s Refine Results
  1. 1001
  2. 1002

    Fig 13 - by Jianbo Jia (717814)

    Published 2024
    Subjects:
  3. 1003
  4. 1004
  5. 1005
  6. 1006
  7. 1007
  8. 1008
  9. 1009

    The Anion [Mg<sub>6</sub>Cl<sub>8</sub>Cp*<sub>5</sub>]<sup>-</sup>:  A Final Intermediate on the Way to the Molecular Donor-Free Grignard Compound MgClCp*? by Jean Vollet (2644651)

    Published 2006
    “…At a slightly higher temperature and by stepwise decrease of the diethyl ether concentration before reaction, a preferred formation of metal clusters such as dodekakispentamethylcyclopentadienylpentaconta-aluminum, Al<sub>50</sub>Cp*<sub>12</sub>, was frequently observed. …”
  10. 1010
  11. 1011
  12. 1012
  13. 1013
  14. 1014
  15. 1015

    Image_1_Decrease in Serum Urate Level Is Associated With Loss of Visceral Fat in Male Gout Patients.tif by Zijing Ran (11429935)

    Published 2021
    “…Subjects included had all been treated with urate-lowering therapy (ULT) (febuxostat 20–80 mg/day or benzbromarone 25–50 mg/day, validated by the medical record). …”
  16. 1016
  17. 1017
  18. 1018
  19. 1019

    The TLR4 activator LPS decreases photoreceptor viability and reducesWnt-mediated protection from oxidative stress. by Hyun Yi (57741)

    Published 2012
    “…White bars, no H<sub>2</sub>O<sub>2</sub>; black bars, with H<sub>2</sub>O<sub>2</sub>. Mean ± SD, *p<0.05 no additions with H<sub>2</sub>O<sub>2</sub> (n = 5) compared with Wnt3a (n = 4); #p<0.05 50 µg/ml LPS+Wnt3a (n = 5) compared with Wnt3a+ H<sub>2</sub>O<sub>2</sub> (n = 4). …”
  20. 1020

    DataSheet5_First-Line ICI Monotherapies for Advanced Non-small-cell Lung Cancer Patients With PD-L1 of at Least 50%: A Cost-Effectiveness Analysis.docx by Qiao Liu (346535)

    Published 2021
    “…</p><p>Conclusion: For advanced NSCLC patients with PD-L1 of at least 50%, cemiplimab was a cost-effective option compared with pembrolizumab and a dominant alternative against atezolizumab. …”